Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV-1 Infection

In brief

The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but integrase strand transfer inhibitor (INSTI) naive.

Key facts

Study ID

NCT02275065

Run by

Gilead Sciences

People needed

23

Starts

2014-10-24

Expected to finish

2015-01-29

Last updated by the study team

2020-11-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Berkeley, California, United States
• Study site — Davis, California, United States
• Study site — Long Beach, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Francisco, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Fort Lauderdale, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Vero Beach, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Berkley, Michigan, United States
• Study site — Newark, New Jersey, United States
• Study site — Santa Fe, New Mexico, United States
• Study site — Dallas, Texas, United States
• Study site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.